Genetic vascular anomaly

Genetic vascular anomalies represent a broad group of rare disorders characterized by abnormal development of blood vessels and/or lymphatic vessels that arise due to underlying genetic mutations. This Orphanet category (ORPHA:211240) serves as a classification grouping for vascular anomalies with a confirmed or suspected genetic basis, encompassing a wide spectrum of conditions including capillary malformations, venous malformations, arteriovenous malformations, lymphatic malformations, and combined vascular malformations. These anomalies can affect virtually any organ system, including the skin, soft tissues, bones, brain, and visceral organs. Clinical features vary widely depending on the specific subtype but commonly include visible vascular birthmarks, soft tissue or bony overgrowth, pain, swelling, bleeding, and functional impairment of affected structures. Some genetic vascular anomalies are associated with overgrowth syndromes (such as those caused by PIK3CA-related mutations), while others may involve high-flow arteriovenous shunting that can lead to cardiac complications. Many of these conditions are caused by somatic mosaic mutations in genes involved in the RAS/MAPK or PI3K/AKT/mTOR signaling pathways, though some follow germline inheritance patterns. Management is typically multidisciplinary, involving dermatologists, interventional radiologists, vascular surgeons, and geneticists. Treatment options include compression therapy, sclerotherapy, embolization, surgical resection, and increasingly, targeted pharmacological therapies such as sirolimus (an mTOR inhibitor) or alpelisib (a PI3K inhibitor) for specific molecular subtypes. Early genetic diagnosis through molecular testing can guide personalized treatment strategies and improve outcomes.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Genetic vascular anomaly